Healthcare company Organon (NYSE:OGN) said on Monday that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals' hormone-free copper intrauterine device (IUD).
The transaction is subject to Hart-Scott-Rodino review and US Food and Drug Administration (FDA) approval of alternate supply chain entities.
MIUDELLA, the first hormone-free copper IUD approved in the United States in 40 years, received FDA approval in February 2025 for up to three years of pregnancy prevention but is not yet commercially available. The device features a flexible frame and a preloaded inserter with a 3.7mm tapered insertion tube.
Under the deal, Organon will pay USD27.5m at closing, with potential sales-based milestone payments of up to USD505m and tiered double-digit royalties on net sales.
Immedica Pharma gains European approval to extend Efmody use in adrenal insufficiency
Neurocrine agrees acquisition of Soleno Therapeutics
NeuroSense's PrimeC composition receives Brazilian patent
Lilly's Foundayo (orforglipron) weight loss pill gains US FDA approval
Abbisko Therapeutics' FGFR4 inhibitor irpagratinib granted orphan designation in Europe for HCC
US FDA approves i-Lumen Scientific's i-SIGHT2 clinical study for dry AMD
Lilly to acquire Centessa Pharmaceuticals for up to USD47 per share
ALK secures EU approval for EURneffy 1 mg as needle-free adrenaline option for children
Sanofi secures EU approval for Rezurock in chronic graft-versus-host disease
Boston Scientific receives FDA clearance for Asurys fluid management system
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Rocket Pharmaceuticals secures FDA approval for Kresladi gene therapy in severe LAD-I
Pharming receives positive CHMP opinion for Joenja marketing authorisation
Biocytogen partner NEOK Bio secures FDA IND clearance for cancer therapy candidate